Christine B. Baltus

Christine B. Baltus

Auto-generated profile, based on publicly available information

Christine B. Baltus

McSAF, 1 rue Claude Thion, 37000 Tours, France

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CBChristine B. Baltus
Christine B. Baltus
RJRadek Jorda
Radek Jorda
CMChristophe Marot
Christophe Marot
KBKarel Berka
Karel Berka
VBVáclav Bazgier
Václav Bazgier
MVMarie-Claude Viaud-Massuard
Marie-Claude Viaud-Massuard

17 January 2020 in ACS Omega
Verified
Journal Article
Open access
OFOfelia Feuillâtre
Ofelia Feuillâtre
CGCamille Gély
Camille Gély
SHSteve Huvelle
Steve Huvelle
CBChristine B. Baltus
Christine B. Baltus
LJLudovic Juen
Ludovic Juen
CMCamille Martin
Camille Martin
Antibody–drug conjugates (ADCs) are the spearhead of targeted therapies. According to the technology used, the conjugation of a cytotoxic drug to an antibody can produce suboptimal heterogeneous species, impacting the overall efficacy. Herein, we describe the synthesis of HER2-targeting ADCs with three disulfide rebridging heads, allowing homogeneous and site-specific bioconjugation: dibromomaleimide (DBM), dithiomaleimide (DTM), and hybrid thio-bromomaleimide (TBM) chemical bricks to combine the properties of both previously used heads. The primary purpose of this study was to compare the reactivity of these three chemical bricks in the bioconjugation process. Then, the resulting ADCs were evaluated in terms of physicochemical stability, binding, and biological activity. We have demonstrated that the higher percentage of a drug-to-antibody ratio of 4 was obtained with TBM. Additionally, the reaction time was drastically reduced with TBM in comparison to DTM. The three ADCs showed good binding to HER2 and in vitro cytotoxicity, which validate the TBM structure as an attractive alternative scaffold for rebridging bioconjugation.

10 November 2010 in ACS Combinatorial Science
Verified
Journal Article
Closed access
John SpencerJohn Spencer
John Spencer
CBChristine B. Baltus
Christine B. Baltus
HPHiren Patel
Hiren Patel
NPNeil J. Press
Neil J. Press
SCSamantha K. Callear
Samantha K. Callear
SCSimon Coles
Simon Coles

1 April 2016 in Royal Society Open Science
Verified
Journal Article
Open access
GRGavin W. Roffe
Gavin W. Roffe
SBSarote Boonseng
Sarote Boonseng
CBChristine B. Baltus
Christine B. Baltus
SCSimon Coles
Simon Coles
IDIain J. Day
Iain J. Day
John SpencerJohn Spencer
John Spencer
The SCN ligand 2-{3-[(methylsulfanyl)methyl]phenyl}pyridine, 1, has been synthesized starting from an initial Suzuki–Miyaura (SM) coupling between 3-((hydroxymethyl)phenyl)boronic acid and 2-bromopyridine. The C–H activation of 1 within situformed Pd(MeCN)4(BF4)2has been studied and leads to a mixture of palladacycles, which were characterized by X-ray crystallography. The monomeric palladacycle LPdCl 6, where L-H = 1, has been synthesized, and tested in SM couplings of aryl bromides, where it showed moderate activity. Density functional theory and the atoms in molecules (AIM) method have been used to investigate the formation and bonding of 6, revealing a difference in the nature of the Pd–S and Pd–N bonds. It was found that S-coordination to the metal in the rate determining C–H bond activation step leads to better stabilization of the Pd(II) centre (by 13–28 kJ mol−1) than with N-coordination. This is attributed to the electron donating ability of the donor atoms determined by Bader charges. The AIM analysis also revealed that the Pd–N bonds are stronger than the Pd–S bonds influencing the stability of key intermediates in the palladacycle formation reaction pathway.

1 March 2013 in Tetrahedron Letters
Verified
Journal Article
Closed access
CBChristine B. Baltus
Christine B. Baltus
ICIrina S. Chuckowree
Irina S. Chuckowree
NPNeil J. Press
Neil J. Press
IDIain J. Day
Iain J. Day
SCSimon Coles
Simon Coles
John SpencerJohn Spencer
John Spencer

28 May 2015 in Molecules
Verified
Journal Article
Open access
PDF file
ALAlessandra Longo
Alessandra Longo
MLMariangela Librizzi
Mariangela Librizzi
ICIrina S. Chuckowree
Irina S. Chuckowree
CBChristine B. Baltus
Christine B. Baltus
John SpencerJohn Spencer
John Spencer
Claudio LuparelloClaudio Luparello
Claudio Luparello
BC-11 is an easily synthesized simple thiouronium-substituted phenylboronic acid, which has been shown to be cytotoxic on triple negative MDA-MB231 breast cancer cells by inducing a perturbation of cell cycle when administered at a concentration equal to its ED50 at 72 h (117 μM). Exposure of cells to BC-11, either pre-absorbed with a soluble preparation of the N-terminal fragment of urokinase-plasminogen activator (uPa), or in co-treatment with two different EGFR inhibitors, indicated that: (i) BC-11 acts via binding to the N-terminus of the enzyme where uPa- and EGF receptor-recognizing sites are present, thereby abrogating the growth-sustaining effect resulting from receptor binding; and (ii) the co-presence of the EGFR inhibitor PD153035 potentiates BC-11’s cytotoxicity. Exposure of cells to a higher concentration of BC-11 corresponding to its ED75 at 72 h (250 μM) caused additional impairment of mitochondrial activity, the production of reactive oxygen species and promotion of apoptosis. Therefore, BC-11 treatment appears to show potential for the development of this class of compounds in the prevention and/or therapy of “aggressive” breast carcinoma.